REVIEW PAPER
Risk associated with the use of 5-alpha reductase inhibitors with minoxidil in treatment of male androgenetic alopecia – literature review
More details
Hide details
1
Intensive Care Unit, Oncology Centre, Katowice, Poland
2
Department of General and Oncological Surgery, Provincial Hospital of St. Luke, Tarnów, Poland
3
Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland
Corresponding author
Maciej Kuca
Intensive Care Unit, Oncology Centre, Katowice, Poland
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Male androgenic alopecia (AGA), is an age-related, genetic, progressive condition affecting more than half of the male population over the age of fifty. 5-alpha reductase inhibitors combined with minoxidil, commonly used in AGA therapy, are associated with potential risk of side-effects. The aim of the article was to ascertain the risk connected with the use of 5-alpha reductase inhibitors with minoxidil in AGA treatment.
Review methods:
A comprehensive evaluation of the literature was conducted utilizing the electronic databases: PubMed
and Google Scholar. Key terms included “androgenic alopecia”, “finasteride”, “dutasteride”, “minoxidil”, “5α-reductase inhibitors”, “side-effects”, and variations of these terms. The literature review considered articles published between 2016 – 2024.
Brief description of the state of knowledge:
The only two drugs registered in the treatment of male AGA are finasteride 1mg and topical minoxidil. Most common side-effects of finesteride 1 mg are erectile dysfunctions, decreased libido and ejaculatory dysfunctions. Dutasteride is used in AGA therapy off-label and associated with similar side-effects as finasteride. The side-effects of 5-alpha reductase inhibitors usually pass after cessation of the therapy. Side-effects with topical minoxidil are highly uncommon. However, some patients using minoxidil 5% may suffer from scalp irritation, hypertrichosis and pruritus.
Summary:
5-alpha reductase inhibitors with minoxidil in AGA therapy, administered in accordance with the Polish
Dermatological Society’s recommendations and the current state of medical knowledge, have a minimal risk of side effects.
REFERENCES (43)
1.
Courtney A, Triwongwarant D, Chim I, et al. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):1919–1922.
https://doi.org/10.1080/146565....
2.
Nestor MS, Ablon G, Gade A, et al. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021 Dec;20(12):3759–3781.
https://doi.org/10.1111/jocd.1....
4.
York K, Meah N, Bhoyrul B, et al. A review of the treatment of male pattern hair loss. Expert Opin Pharmacother. 2020 Apr;21(5):603–612.
https://doi.org/10.1080/146565....
5.
Rosenthal A, Conde G, Greco JF, et al. Management of androgenic alopecia: a systematic review of the literature. J Cosmet Laser Ther. 2024 Jan-Jun;26(1–4):1–16.
https://doi.org/10.1080/147641....
6.
Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286–294.
https://doi.org/10.1111/jdv.17....
7.
Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136–141.e5.
https://doi.org/10.1016/j.jaad....
8.
Fertig RM, Gamret AC, Darwin E, et al. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatol Online J. 2017 Nov 11;23(11):13030/qt24k8q743.
9.
Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2257–2263.
https://doi.org/10.1111/jdv.15....
10.
Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021 Mar;84(3):737–746.
https://doi.org/10.1016/j.jaad....
11.
Motofei IG, Rowland DL, Baconi DL, et al. Androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018 Apr;17(4):407–412.
https://doi.org/10.1080/147403....
14.
1Phillips TG, Slomiany WP, Allison R. Hair Loss: Common Causes and Treatment. Am Fam Physician. 2017 Sep 15;96(6):371–378.
15.
Alessandrini A, Bruni F, Piraccini BM, et al. Common causes of hair loss – clinical manifestations, trichoscopy and therapy. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):629–640.
https://doi.org/10.1111/jdv.17....
17.
Asanad K, Sholklapper T, Samplaski MK, et al. Global online interest in finasteride sexual side effects. Int J Impot Res. 2024 Jun;36(4):408–413.
https://doi.org/10.1038/s41443....
18.
Zhou C, Li X, Wang C, et al. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol. 2021 Dec;61(3):403–423.
https://doi.org/10.1007/s12016....
19.
Hughes EC, Syed HA, Saleh D. Telogen Effluvium. 2024 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
20.
Christensen RE, Tan I, Jafferany M. Recent advances in trichotillomania: a narrative review. Acta Dermatovenerol Alp Pannonica Adriat. 2023 Dec;32(4):151–157.
21.
Haskin A, Kwatra SG, Aguh C. Breaking the cycle of hair breakage: pearls for the management of acquired trichorrhexis nodosa. J Dermatolog Treat. 2017 Jun;28(4):322–326.
https://doi.org/10.1080/095466....
24.
Brzezińska-Wcisło L, Rakowska A, Rudnicka L, et al. Androgenetic alopecia. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Dermatol Rev/Przegl Dermatol. 2018, 105:1–18.
https://doi.org/10.5114/dr.201....
25.
Zito PM, Bistas KG, Patel P, et al. Finasteride. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
28.
Motofei IG, Rowland DL, Tampa M, et al. Finasteride and androgenic alopecia; from therapeutic options to medical implications. J Dermatolog Treat. 2020 Jun;31(4):415–421.
https://doi.org/10.1080/095466....
31.
Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022 Nov;33(7):2946–2962.
https://doi.org/10.1080/095466....
32.
Hirshburg JM, Kelsey PA, Therrien CA, et al. Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. J Clin Aesthet Dermatol. 2016 Jul;9(7):56–62.
33.
Asfour L, Cranwell W, Sinclair R. Male Androgenetic Alopecia. 2023 Jan 25. In: Feingold KR, Anawalt B, Blackman MR, et al. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
34.
Charakterystyka produktu leczniczego.
https://rejestrymedyczne. ezdrowie.gov.pl/api/rpl/medicinal-products/37812 characteristic (access: 15.09.2024).
35.
Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, et al. Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice. J Drugs Dermatol. 2022 Jul 1;21(7):742–747.
https://doi.org/10.36849/JDD.6....
36.
Rodríguez-Cuadrado FJ, Pinto-Pulido EL, Fernández-Parrado M. Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature. Eur J Dermatol. 2023 Feb 1;33(1):72. https:// doi.org/10.1684/ejd.2023.4443.
37.
Sánchez-Meza E, Ocampo-Candiani J, Gómez-Flores M, et al. Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e806-e808.
https://doi.org/10.1111/jdv.18....
38.
Saceda-Corralo D, Rodrigues-Barata AR, Vañó-Galván S, et al. Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J Trichology. 2017 Jul-Sep;9(3):143–145.
https://doi. org/10.4103/ijt.ijt_73_16.
41.
Stoehr JR, Choi JN, Colavincenzo M, et al. Off-Label Use of Topical Minoxidil in Alopecia: A Review. Am J Clin Dermatol. 2019 Apr;20(2):237–250.
https://doi.org/10.1007/s40257....
42.
Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021 Mar;84(3):737–747.
https://doi.org/10.1016/j.jaad....
43.
Beach RA, McDonald KA, Barrett BM, et al. Side effects of low-dose oral minoxidil for treating alopecia. J Am Acad Dermatol. 2021 May;84(5):e239-e240.
https://doi.org/10.1016/j.jaad....